SSS Sunvest Minerals Corp

Stem Cell Ther apeutics Corp. (TSX VENTURE:SSS)(OTCQX:SCTPF), a
biopharmaceutical immuno-oncology company developing cancer stem cell-related
therapeutics, today announced that it has entered into an option agreement to
exclusively license worldwide rights to a panel of fully human monoclonal
antibodies targeting the SIRPa protein (CD172a). The technology was developed by
scientists at the University Health Network, the University of Toronto, through
the Toronto Recombinant Antibody Centre (TRAC), and The Hospital for Sick
Children (SickKids), in Toronto, Ontario.


SIRPa is the ligand of CD47, a molecule upregulated on many hematological and
solid tumors. CD47 delivers a "do not eat" signal that su ppresses macrophage
phagocytosis, allowing cancer cells, including cancer stem cells, to escape
immune-mediated destruction. Stem Cell Therapeutics (SCT) is currently
developing a CD47 antagonist, using a modified version of the native SIRPa
protein fused to an immunoglobulin Fc region. This SIRPaFc fusion protein has
shown remarkable anti-leukemic activity both in vitro and in human xenograft
models, and SCT recently announced that the program has entered the IND-enabling
phase of drug development. The company expects to report further updates at the
upcoming annual meeting of the American Society of Hematology (December 7-10,
2013).


"Targeting the CD47/SIRPa pathway can eliminate bot h bulk cancer cells and
cancer stem cells, and engages both the innate and the adaptive arms of the
immune system," commented SCT's Chief Scientific Officer, Dr. Bob Uger.
"Antibody blockade of SIRPa is a promising approach to activate the anti-tumor
activity of macrophages against both liquid and solid tumors, and has the
potential as both a monotherapy and combination therapy with other anti-cancer
antibodies."


"The CD47/SIRPa axis is one of the most promising a nd compelling
next-generation immunotherapy targets in the fight against cancer," remarked
SCT's Chief Executive Officer, Dr. Niclas Stiernholm. "Having recently an
nounced the advancement of our SIRPaFc program into formal IND-enabling studies,
a program we believe is the best-in-class CD47 antagonist currently in
development, reinforcing our industry-leading position in this pathway with a
complementary antibody program against the SIRPa protein makes eminent sense."


The execution of the definitive license agreement is subject to final
due-diligence and certain conditions being met by SCT over the next nine months.
The license agreement will contain customary terms and provisions for assets at
this stage of development, including an initial license consideration, milestone
payments, royalties on sales and sublicensing terms.


SCT Annual and Special Meeting

The company's Annual and Special Meeting of shareholders will be held today at
3:00 pm in the company's offices at 96 Skyway Avenue, Toronto, Ontario, M9W 4Y9.
The meeting will include an audio broadcast. To access, please use the following
details:




Date:                 Thursday, October 17, 2013              
Time:                 3:00 PM Eastern                         
Dial-in Number:       (647) 427-7450 or (888) 231-8191        
Taped Replay:         (416) 849-0833 or (855) 859-2056        
Reference Number:     88104376                                



About Cancer Stem Cells:

The cancer stem cell (CSC) concept postulates that the growth of tumors is
driven by a rare population of dedicated cells that have stem cell-like
properties, including self- renewal. While the bulk of a tumor consists of
rapidly proliferating cells and differentiated cells, neither of which is
capable of self-renewal, a small population of CSCs provides for long-term
maintenance of the cancer. Although the CSC concept was first postulated in the
1960s, it wasn't until 1994 that proof of their existence was demonstrated, when
Dr. John Dick and colleagues in Toronto isolated CSCs (known as leukemic stem
cells, or LSCs) from bulk acute myeloid leukemia cells. More recently, CSCs have
been identified in many other human malignancies, including solid tumors such as
bladder, brain, breast, colon, ovarian and prostate cancers. There is
accumulating evidence that CSCs are resistant to conventional chemotherapies and
radiation. Thus, CSCs are thought to be responsible for a phenomenon well known
to oncologists: most patients will experience an initial response to
conventional chemotherapies but will ultimately relapse. To cure cancer CSCs
need to be destroyed, but the current armament of therapies is poorly equipped
to do so.


About Stem Cell Therapeutics:

Stem Cell Therapeutics Corp. (SCT) is a biopharmaceutical immuno-oncology
company advancing cancer stem cell discoveries into novel and innovative cancer
therapies. Building on over half a century of leading and groundbreaking
Canadian stem cell research, the company is supported by established links to a
group of Toronto academic research institutes and cancer treatment centers,
representing one of the world's most acclaimed cancer research hubs. The Company
has two premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody
(mAb), which target two key immunoregulatory pathways that tumor cells exploit
to evade the host immune system. SIRPaFc is an antibody-like fusion protein that
blocks the activity of CD47, a molecule that is upregulated on cancer stem cells
in AML and several other tumors. The CD200 mAb is a fully human monoclonal
antibody that blocks the activity of CD200, an immunosuppressive molecule that
is overexpressed by many hematopoietic and solid tumors. SCT's clinical stage
programs include the recently in-licensed program focused on the structure of
tigecycline, which is currently being evaluated in a multi-centre Phase I study
in patients with acute myeloid leukemia (AML), as well as TTI-1612, a non-cancer
stem cell asset that recently completed a 28-patient Phase I trial in
interstitial cystitis ("IC") patients. For more information, visit:
www.stemcellthera.com.


Caution Regarding Forward-Looking Information:

This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include changing market conditions; the successful and timely completion
of pre-clinical and clinical studies; the establishment of corporate alliances;
the impact of competitive products and pricing; new product development risks;
uncertainties related to the regulatory approval process or the ability to
obtain drug product in sufficient quantity or at standards acceptable to health
regulatory authorities to complete clinical trials or to meet commercial demand;
and other risks detailed from time to time in SCT's ongoing quarterly and annual
reporting. Except as required by applicable securities laws, SCT undertakes no
obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
James Parsons
Chief Financial Officer
+1 416 595 0627
jparsons@stemcellthera.com
www.stemcellthera.com


Investor Contact:
ProActive Capital
Jeff Ramson/Kirin Smith
+1 646-863-6519
jramson@proactivecapital.com / ksmith@proactivecapital.com

Sunvest Minerals Corp (TSXV:SSS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Sunvest Minerals Corp (TSXV:SSS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024